Eye involvement in primary central nervous system lymphoma
| Autor: | Alexandra L. Farrall, Justine R. Smith |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Lymphoma genetic structures Eye disease Global Health Malignancy Retina Central Nervous System Neoplasms 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine Prevalence medicine Humans business.industry Eye Neoplasms Incidence (epidemiology) Primary central nervous system lymphoma medicine.disease eye diseases Vitreous Body Ophthalmology Cohort 030221 ophthalmology & optometry sense organs business Diffuse large B-cell lymphoma 030217 neurology & neurosurgery Cohort study |
| Zdroj: | Survey of Ophthalmology. 65:548-561 |
| ISSN: | 0039-6257 |
| DOI: | 10.1016/j.survophthal.2020.02.001 |
| Popis: | Primary central nervous system lymphoma (PCNSL) may manifest initially in the eye (termed vitreoretinal lymphoma or VRL) or in non-ocular CNS compartments, or in both. The nature of the onset of PCNSL implies two clinical specialists - ophthalmologists and neuro-oncologists - independently may assess the primary presentation of this rare malignancy. Clinically relevant perspectives on expectations of PCNSL manifestation in both ocular and non-ocular CNS compartments would help inform management practices in each specialty, which should impact clinical outcomes. A recent increase in the number of published PCNSL cohort studies provides new opportunity to review the current prevalence rates of ocular involvement, and the timing of this involvement over the course of disease. In PCNSL cohorts defined by non-ocular CNS compartment involvement, with or without ocular involvement (termed "PCNSL ± ocular involvement" cohorts), mean rates of concomitant VRL at diagnosis, or at any time during the course, are 10% and 16%, respectively. Only a few individuals within this cohort group present with exclusive eye disease ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect